Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer

Ryu, Jee-Yeon; Choi, Yong‐Keel; Won, Eun-Jeong; Hui, Emmanuel; Kim, Ho‐Shik; Cho, Young-Seok; Yoon, Tae‐Jong

doi:10.1007/s12274-020-2773-1

Cited by 13 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of this study showed that targeting K-Ras using CRISPR/Cas9 technology can significantly enhance the apoptotic effects of cetuximab. The findings also showed that the use of CRISPR/Cas9 to target K-Ras in mice with KRAS-mutated CRC significantly reduced tumor size and enhanced the effect of cetuximab in the induction of apoptosis [107]. It should be noted that cetuximab is an EGFR inhibitor used to treat colorectal cancer with unmutated K-Ras [108].…”

Section: Crispr/cas9 Gene Editing Applications In Overcoming Drug Res...mentioning

confidence: 89%

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

et al. 2022

View full text Add to dashboard Cite

The CRISPR/Cas9 system is an RNA-based adaptive immune system in bacteria and archaea. Various studies have shown that it is possible to target a wide range of human genes and treat some human diseases, including cancers, by the CRISPR/Cas9 system. In fact, CRISPR/Cas9 gene editing is one of the most efficient genome manipulation techniques. Studies have shown that CRISPR/Cas9 technology, in addition to having the potential to be used as a new therapeutic approach in the treatment of cancers, can also be used to enhance the effectiveness of existing treatments. Undoubtedly, the issue of drug resistance is one of the main obstacles in the treatment of cancers. Cancer cells resist anticancer drugs by a variety of mechanisms, such as enhancing anticancer drugs efflux, enhancing DNA repair, enhancing stemness, and attenuating apoptosis. Mutations in some proteins of different cellular signaling pathways are associated with these events and drug resistance. Recent studies have shown that the CRISPR/Cas9 technique can be used to target important genes involved in these mechanisms, thereby increasing the effectiveness of anticancer drugs. In this review article, studies related to the applications of this technique in overcoming drug resistance in cancer cells will be reviewed. In addition, we will give a brief overview of the limitations of the CRISP/Cas9 gene-editing technique.

show abstract

Section: Crispr/cas9 Gene Editing Applications In Overcoming Drug Res...mentioning

confidence: 89%

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Perumal et al demonstrated that CRISPR technology successfully blocked the tumor suppressor phosphatase and homologous tensin ( PTEN ) in NSCLC, which resulted in increased cancer growth by the promoting Akt pathway [ 58 ]. In colorectal cancer associated with KRAS or BRAF mutations, preclinical studies have identified novel pathways that could eventually be used as clinical targets through genome-wide CRISPR screening in which large libraries of guide RNAs targeted against numerous genes of interest result in large scale knockdown [ 59 , 60 ]. These preclinical advances have paved the way for investigation of the clinical applications of CRISPR/Cas9 in the development of cancer therapeutics.…”

Section: Crispr In Oncology—preclinical Usementioning

confidence: 99%

The Potential Revolution of Cancer Treatment with CRISPR Technology

Stefanoudakis

Kathuria‐Prakash

Sun

et al. 2023

Cancers

View full text Add to dashboard Cite

Immuno-oncology (IO) and targeted therapies, such as small molecule inhibitors, have changed the landscape of cancer treatment and prognosis; however, durable responses have been difficult to achieve due to tumor heterogeneity, development of drug resistance, and adverse effects that limit dosing and prolonged drug use. To improve upon the current medicinal armamentarium, there is an urgent need for new ways to understand, reverse, and treat carcinogenesis. Clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) 9 is a powerful and efficient tool for genome editing that has shown significant promise for developing new therapeutics. While CRISPR/Cas9 has been successfully used for pre-clinical cancer research, its use in the clinical setting is still in an early stage of development. The purpose of this review is to describe the CRISPR technology and to provide an overview of its current applications and future potential as cancer therapies.

show abstract

“…In addition, bio-reducible disulfide bonds of nanocarriers can be adjusted to improve degradation and endosomal escape [98]. In addition, the Cas9 protein can be modified to enhance the encapsulation efficiency of NPs [99,100].…”

Section: Pre-assembled Ribonucleoprotein (Rnp) Complex Deliverymentioning

confidence: 99%

Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics

et al. 2022

Self Cite

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers worldwide, and its incidence is increasing. PDAC often shows resistance to several therapeutic modalities and a higher recurrence rate after surgical treatment in the early localized stage. Combination chemotherapy in advanced pancreatic cancer has minimal impact on overall survival. RNA interference (RNAi) is a promising tool for regulating target genes to achieve sequence-specific gene silencing. Here, we summarize RNAi-based therapeutics using nanomedicine-based delivery systems that are currently being tested in clinical trials and are being developed for the treatment of PDAC. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) genome editing has been widely used for the development of cancer models as a genetic screening tool for the identification and validation of therapeutic targets, as well as for potential cancer therapeutics. This review discusses current advances in CRISPR/Cas9 technology and its application to PDAC research. Continued progress in understanding the PDAC tumor microenvironment and nanomedicine-based gene therapy will improve the clinical outcomes of patients with PDAC.

show abstract

Gene editing particle system as a therapeutic approach for drug-resistant colorectal cancer

Cited by 13 publications

References 27 publications

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer

The Potential Revolution of Cancer Treatment with CRISPR Technology

Gene Therapy Using Nanocarriers for Pancreatic Ductal Adenocarcinoma: Applications and Challenges in Cancer Therapeutics

Contact Info

Product

Resources

About